<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81974">
  <stage>Registered</stage>
  <submitdate>19/04/2007</submitdate>
  <approvaldate>24/04/2007</approvaldate>
  <actrnumber>ACTRN12607000222448</actrnumber>
  <trial_identification>
    <studytitle>The effect of oral rivaroxaban in treating and in the long term prevention in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.</studytitle>
    <scientifictitle>The effect of oral direct factor Xa inhibitor rivaroxaban in treating (Bay 59-7939 / 11702) and in the long term prevention (Bay 59-7939 / 11899) in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.</scientifictitle>
    <utrn />
    <trialacronym>Einstein VTE III and Einstein Extension</trialacronym>
    <secondaryid>ClinicalTrials.org: NCT00439725</secondaryid>
    <secondaryid>ClinicalTrials.org: NCT00439777</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Deep vein thrombosis</healthcondition>
    <healthcondition>Pulmonary embolism</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients allocated to the rivaroxaban arm of the prevention trial (Bay 59-7939 / 11702) will receive rivaroxaban 15 mg twice daily orally for a total of 3 weeks and thereafter patients will receive rivaroxaban 20 mg once daily. 

Patients from both the rivaroxaban and enoxaparin treatment arms will be treated for 3, 6 or 12 months depending on the risk profile of the patients and the preference of the investigator.

Patients continuing in the extension study (Bay 59-7939 / 11899) will receive rivaroxaban or matching placebo 20 mg orally once daily. Treatment duration will be 6 or 12 months and should be indicated prior to randomisation.</interventions>
    <comparator>Patients allocated to the comparator arm will receive enoxaparin 1.0 mg / kg twice daily for at least 5 days in combination with vitamin K antagonist given subcutaneously. Enoxaparin will continue until the International Normalised Ratio is greater than or equal to 2.0 on two consecutive occasions, with an advised overlap with VKA for 4 to 5 days.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary efficacy outcome is symptomatic recurrent venous thromboembolism (VTE). </outcome>
      <timepoint>Measured at the first occurrence from time of randomisation, then once a month until the end of the follow up period.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically relevant bleeding.</outcome>
      <timepoint>Measured at the first occurrence from time of randomisation, then once a month until the end of the follow up period.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria for Bay 59-7939 / 11702. Confirmed acute symptomatic proximal deep vein thrombosis or confirmed acute symptomatic pulmonary embolism. 
Active bleeding.Inclusion criteria for Bay 59-7939 / 11899.Confirmed acute symptomatic deep vein thrombosis or pulmonary embolism who have been treated for 6 or 12 months with vitamin K antagonist.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria for 11702Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of deep vein thrombosis (DVT) and/or pulmonary embolism (PE).Other indication for VKA other than DVT and/or PE. More than 36 hours pre-randomisation treatment with therapeutic dosages of low molecular weight heparin / fondaparinux or more than a single dose of VKA prior to randomisation.Significant renal or liver disease.
Exclusion criteria for 11899Other indication for VKA other than DVT and/or PE.Significant renal or liver disease.Systolic blood pressure greater than 180 mmHg or diastolic greater than 110 mmHgActive bleeding. Bacterial endocarditis.Active bleeding or high risk for bleeding.Life expectancy less than 3 months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>An interactive voice response system (IVRS) will be used to allocate treatments.</concealment>
    <sequence>Computer generated random code.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>The extension trial (Bay 59-7939 / 11899) is a double blind (patients, assessors, clinician and data analyst), placebo controlled trial for patients with confirmed symptomatic deep vein thrombosis or pulmonary embolism who completed 6 or 12 months of treatment with rivaroxaban.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>24/04/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>5193</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer Australia Limited</primarysponsorname>
    <primarysponsoraddress>875 Pacific Highway Pymble NSW 2073</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bayer Australia Limited</fundingname>
      <fundingaddress>875 Pacific Highway Pymble NSW 2073</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Johnson and Johnson Pharmaceutical Research Development</fundingname>
      <fundingaddress>Raritan NJ 08869</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C. (Collaborator 11702b)
Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C. (Collaborator 11899)</sponsorname>
      <sponsoraddress>Raritan, New Jersey</sponsoraddress>
      <sponsorcountry>United States of America</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic PE with or without symptomatic DVT (Einstein-PE). (11702b)

This is a multicenter, randomized, double-blind, placebo-controlled, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT or PE who completed 6 or 12 months of treatment with rivaroxaban or VKA are eligible for this trial (Einstein-Extension study). (11899)</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Queen Elizabeth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>19/03/2007</ethicapprovaldate>
      <hrec>2007018</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Gold Coast Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>28/03/2007</ethicapprovaldate>
      <hrec>200715</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Tim Brighton</name>
      <address>Department of Haematology
Prince of Wales Hospital 
Barker Street
Randwick NSW 2031</address>
      <phone>+61 2 93829013</phone>
      <fax>+61 2 93829116</fax>
      <email>tim.brighton@sesaihs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Tim Brighton</name>
      <address>Department of Haematology
Prince of Wales Hospital
Barker Street
Randwick NSW 2031</address>
      <phone>+61 2 93829013</phone>
      <fax>+61 2 93829116</fax>
      <email>tim.brighton@sesaihs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>